Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma.
Open accessThe DOI matches its Crossref record.
Abstract
Analysis of the age incidence curves for unilateral and bilateral retinoblastoma led Knudson to propose that hereditary tumours may arise by a single event and sporadic tumours by a two stage mutation process. It has been suggested recently that sporadic renal cell carcinoma may arise from a two stage mutation process. We analysed the age incidence curves for symptomatic renal cell carcinoma (n = 26) and cerebellar haemangioblastoma (n = 68) in 109 patients with von Hippel-Lindau (VHL) disease, and compared them to 104 patients with sporadic renal cell carcinoma and 43 patients with sporadic cerebellar haemangioblastoma. The age incidence curves for renal cell carcinoma and cerebellar haemangioblastoma in VHL disease were compatible with a single mutation model, whereas the age incidence curves for sporadic renal cell carcinoma and cerebellar haemangioblastoma suggested a two stage mutation process. These data are compatible with the VHL gene functioning as a recessive tumour suppressor gene. Sporadic cerebellar haemangioblastoma and some renal cell carcinoma may arise from somatic mutations inactivating both alleles at the VHL locus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Self-citationLonser, R. R., Glenn, G. M., Walther, M., Chew, E. Y., Libutti, S. K., Linehan, W. M., & Oldfield, E. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13643-4 · Cited by 1,600
VHL, the story of a tumour suppressor gene
Gossage, L., Eisen, T., & Maher, E. R. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3844 · Cited by 774
Self-citationvon Hippel–Lindau disease: A clinical and scientific review
Maher, E. R., Neumann, H. P., & Richard, S. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.175 · Cited by 729
Self-citationMaher, E. R., & Kaelin, W. G. (1997) · Medicine · doi:10.1097/00005792-199711000-00001 · Cited by 528
Self-citationTiming the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Mitchell, T. J., Turajlic, S., Rowan, A., Nicol, D., Farmery, J. H. R., O’Brien, T., Martincorena, I., Tarpey, P., Angelopoulos, N., Yates, L. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.020 · Cited by 513
Genetic analysis of von Hippel-Lindau disease
Nordstrom-O'Brien, M., van der Luijt, R. B., van Rooijen, E., van den Ouweland, A. M., Majoor-Krakauer, D. F., Lolkema, M. P., van Brussel, A., Voest, E. E., & Giles, R. H. (2010) · Human Mutation · doi:10.1002/humu.21219 · Cited by 311
Dreijerink, K., Braga, E., Kuzmin, I., Geil, L., Duh, F.-M., Angeloni, D., Zbar, B., Lerman, M. I., Stanbridge, E. J., Minna, J. D., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131216298 · Cited by 294
Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
Hu, J., Tan, P., Ishihara, M., Bayley, N. A., Schokrpur, S., Reynoso, J. G., Zhang, Y., Lim, R. J., Dumitras, C., Yang, L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01362-2 · Cited by 85
“Detailed studies of von Hippel-Lindau (VHL) disease (a rare hereditary cancer syndrome manifesting as renal, CNS, adrenal, and pancreatic tumors) led to the cloning of the VHL tumorsuppressor gene.(4,5) Somatic mutations of VHL were also identified in as many as 90% of sporadic, non-familial ccRCC cases.”
Background
Metadata
- Authors
- Maher, E. R., Yates, J. R., & Ferguson-Smith, M. A.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 1990-05
- Volume
- 27
- Issue
- 5
- Pages
- 311-314
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2123724520
- Cited by
- 177
- References
- 0
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.